ARTICLE | Strategy

Big Arris deal goes against the grain

December 5, 1994 8:00 AM UTC


Over the last few years, an equity investment by corporate partners has come to be viewed as a requisite seal of approval validating a biotech company's technology. According to this reasoning, the potential upside of an equity stake builds an incentive for the senior partner to make the smaller company's programs succeed. ...